-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Many patients with multiple myeloma eventually develop resistance to treatment, in part because of the drive of cancer stem cells.
if existing treatments do not completely destroy these malignant cancer stem cells, the cancer is likely to continue to relapse.
at the University of California, San Diego School of Medicine are working on a new targeted treatment for myeloma, the silent IRF4 gene, which allows myeloma stem cells and tumor cells to multiply and survive.
past studies have shown that high IRF4 levels are associated with lower total survival rates.
in a study published in Cell Stem cell on January 20, 2021, the team detailed their use of antisant oligonucleotides to inhibit IRF4, an engineered DNA (ION251) designed to bind to genetic material encoded in IRF4 to degrade it.
, ION251 reduces the burden of disease, reduces myeloma stem cell abundance, and improves survival in mice with human myeloma, according to preclinical studies.
results support a recently launched Phase I clinical trial to assess the safety and effectiveness of ION251 in treating myeloma patients, the study authors said.